Skip to main content
Log in

Penetration of teniposide (VM-26) into human intracerebral tumors

Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Thirty-four consenting patients received VM-26 50–100 mg/m2 I.V. before surgical resection of intracerebral tumor, and drug was measured using a high pressure liquid chromatographic technique. Sufficient tumor for analysis was obtained from 29 patients. Brain metastases (13 patients) had higher concentrations of V M-26 than did gliomas (13 patients). Concentrations were comparable in brain metastases and meningiomas (3 patients). Prolonged (24 h) infusion of V M-26 did not appear to result in higher tumor drug concentrations in 5 patients than did rapid (1 h) infusion in 24 patients. Pretreatment with Amphotericin-B 10 mg/m2 12 h and 1 h before VM-26 did not appear to have any effect on VM-26 uptake into 4 intracerebral tumors, although data were limited, and VM-26 concentrations were very high in 1 metastasis. Pretreatment with oral glycerol 500 mg/kg 18 h, 12 h, 6 h, and immediately before I.V. VM-26 may have resulted in increased penetration of VM-26 into 9 tumors, although confirmation is required. Amphotericin-B, glycerol, and operative conditions did not appear to alter VM-26 plasma pharmacokinetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

VM-26:

4′-demethylepipodophyllotoxin 9-(4-6-O-thenylidene-B-D-glucopyranoside)

VP-16:

4′-demethylepipodophyllotoxin 9-(4-6-O-ethylidene-B-D-glucopyranoside)

References

  1. Stewart DJ, Richard M, Hugenholtz H, Dennery J: VP-16 (VP) and VM-26 (V M) penetration into human brain tumors (BT). Proc Am Assoc Cancer Res 24:133, 1983.

    Google Scholar 

  2. Sklansky BD, Mann-Kaplan RS, Reynolds AF, Rosenblum ML, Walker MD: 4′-demethyl-epipodophyllotoxin-B-D-thenylidene glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33:460–467, 1974.

    Google Scholar 

  3. Kessinger A, Lemon HM, Foley JF: VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 63: 511–512, 1979.

    Google Scholar 

  4. Gerosa MA, Di Stefano E, Olivi A: VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: preliminary report. Surgical neurology 15:128–134, 1981.

    Google Scholar 

  5. Maroun JA, Stewart DJ, Young V, Belanger R, Crook AF: Effectiveness of VM-26 in non-small cell carcinoma of the lung (NSCLL) with central nervous system (CNS) metastases. Preliminary results. Proc Am Soc Clin Oncol 1:140, 1982.

    Google Scholar 

  6. Shapiro WR: The chemotherapy of intracerebral vs subcutaneous murine gliomas. Arch Neurol 30:222–226, 1974.

    Google Scholar 

  7. Creaven PJ, Allen LM: PTG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol and Therap 18:227–233, 1975.

    Google Scholar 

  8. Sessa C, D'Incalci M, Farina P, Rossi C, Cavalli F, Mangioni C, Garattini S: Pharmacokinetics of VM-26 after 60 minutes or 24 hours continuous infusion. Proc Amer Assoc Cancer Res 23:128, 1982.

    Google Scholar 

  9. Rausa L, D'Alessandro N, Dusonchet L, Gebbia N, Sanguedolce R, Crescimanno M, Crosta L, Flandina C, Leto G, Tumminello FM: Pharmacological studies on VM-26 (teniposide). Chemioterapia 1:130–136, 1982.

    Google Scholar 

  10. Broggini M, Colombo T, D'Incalci M: Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice. Cancer Treat Rep 67:555–559, 1983.

    Google Scholar 

  11. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Research 42:2474–2479, 1982.

    Google Scholar 

  12. Rosenblum M, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL: Penetration of methylglyoxal bis (guanylhydrazone) into intracerebral tumors in humans. Cancer Research 41:459–462, 1981.

    Google Scholar 

  13. Stewart DJ, Lu K, Benjamin RS, Leavens M, Luna M, Yap HY, Loo TL: Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neuro.Oncol 1:139–144, 1983.

    Google Scholar 

  14. Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL: Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Research 40:3163–3166, 1980.

    Google Scholar 

  15. Groothuis DR, Fischer JM, Vick NA, Bigner DD: Comparative permeability of different glioma models to horseradish peroxidase. Cancer Treat Rep 65 (Suppl 2):13–18, 1981.

    Google Scholar 

  16. Stewart DJ, Richard M, Hugenholtz H, Dennery J, Belanger R, Gerin-Lajoie J, Mompetit V, Nundy D, Prior J, Hopkins HS: Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neuro-Oncol 2:133–139, 1984.

    Google Scholar 

  17. Stewart DJ, Benjamin RS, Luna M, Seifert WE, Loo TL: Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother & Pharm 10:51–54, 1982.

    Google Scholar 

  18. Medoff J, Medoff G, Goldstein MN, Schlessinger D, Kobayashi GS: Amphotericin-B-induced sensitivity to actinomycin-D in drug-resistant HELA cells. Cancer Res 35:2548–2552, 1975.

    Google Scholar 

  19. Medoff G, Kwan CN, Schlessinger D, Kobayashi GS: Potentiation of rifampicin, rifampicin analogs, and tetracycline against animal cells by amphotericin-B and polymyxin-B. Cancer Res 33:1146–1149, 1973.

    Google Scholar 

  20. Levin VA, Landahl HD, Freeman-Dove MA: The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier. J Pharmacokin and Biopharm 4:499–519, 1976.

    Google Scholar 

  21. Barry DI, Paulson OB: Amphotericin-B and the blood-brain barrier to methotrexate. Neurosurgery 10:224–226, 1982.

    Google Scholar 

  22. Sterrett PR, Thompson AM, Chapman AL, Matzke HA: The effects of hyperosmolarity on the blood-brain barrier. A morphological and physiological correlation. Brain Res 77:281–295, 1974.

    Google Scholar 

  23. Rapoport SI, Hori M, Klatzo I: Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol 223: 323–331, 1972.

    Google Scholar 

  24. Neuwelt EA, Diehl JT, Vu LH, Hill SA, Michael AJ, Frenkel EP: Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94:449–454, 1981.

    Google Scholar 

  25. Shapiro WR, Voorhies RM, Basler GA, Blasberg RG: Regional methotrexate entry into experimental rat brain tumors as measured by quantitative autoradiography (QAR). Proc Amer Assoc Cancer Res 23:179, 1982.

    Google Scholar 

  26. Neuwelt EA, Pagel M, Barnett P, Glasberg M, Frenkel EP: Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Res 41:4460–4470, 1981.

    Google Scholar 

  27. Neuwelt EA, Glasberg M, Barnett P, Frenkel EP: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathologic studies. Proc Amer Assoc Cancer Res 24:272, 1983.

    Google Scholar 

  28. Meyer JS, Itoh Y, Okamoto S, Welch KM, Matthew R, Ott EO, Sakaki S, Miyakawa Y, Chabi E, Ericsson AD: Circulatory and metabolic effects of glycerol infusion in patients with recent cerebral infarction. Circulation 51: 701–712, 1975.

    Google Scholar 

  29. Evans WE, Sinkule JA, Crom WR, Dow L, Look T, Rivera G: Pharmacokinetics of teniposide (VM-26) and etoposide (VP-16–213) in children with cancer. Cancer Chemother Pharmacol 7:147–150, 1982.

    Google Scholar 

  30. Stewart DJ, Benvenuto J, Leavens M, Smith R, Cabanillas F, Benjamin RS, Loo Ti Li: Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J Neuro-Oncol 1:357–364, 1983.

    Google Scholar 

  31. Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KD, Burgess MA, Loo TL: Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid. Cancer Research 39:4119–4122, 1979.

    Google Scholar 

  32. Savaraj N, Lu K, Fenn LG, Leavens ME, Stewart DJ, Burgess MA, Benjamin RS, Loo TL: Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone, (AZQ NSC 182986). J Neuro-Oncol 1:15–20, 1983.

    Google Scholar 

  33. Levin VA, Freeman-Dove M, Landahl HD: Permeability characteristics in brain adjacent to tumor in rats. Arch Neurol 32:785–791, 1975.

    Google Scholar 

  34. Levin VA: A pharmacologic basis for brain tumor chemotherapy. Seminars in Oncology 2:57–61, 1975.

    Google Scholar 

  35. Vick NA, Khandekar JD, Bigner DD: Chemotherapy of brain tumors: The ‘blood-brain barrier’ is not a factor. Arch Neurol 34:523–526, 1977.

    Google Scholar 

  36. Booser DJ, Spitzer G, Chiuten DF, Valdivieso M: Epipodophyllotoxins VP-16–213 and VP-16. A phase 1 study of 5-day continuous intravenous infusion (CI) in bronchogenic carcinomas. Proc Amer Soc Clin Oncol 22:508, 1981.

    Google Scholar 

  37. Hasegawa H, Allen JC, Mehta BM, Shapiro WR, Posner JB: Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Neurology 29:1280–1286, 1979.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, D.J., Richard, M.T., Hugenholtz, H. et al. Penetration of teniposide (VM-26) into human intracerebral tumors. J Neuro-Oncol 2, 315–324 (1984). https://doi.org/10.1007/BF00178114

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00178114

Keywords

Navigation